Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Semaglutide D
Semaglutide D Dose 1 · 3 trials · 4 indications
Measured in Percentage
h∙nmol/L
nmol/L
h \* nmol/L
| Arm | Type | Description |
|---|---|---|
| Semaglutide | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Group 1 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 1 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Group 2 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 2 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Group 3 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 3 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Part A: Oral semaglutide | EXPERIMENTAL | Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days |
| Part B: NNC0385-0434 | EXPERIMENTAL | Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days |
| Name | Type | Description |
|---|---|---|
| Semaglutide D Dose 1 | DRUG | Tablet given orally |
| Semaglutide D Dose 2 | DRUG | Tablet given orally |
| Semaglutide D Dose 3 | DRUG | Tablet given orally |
| Semaglutide C Dose 4 | DRUG | Tablet given orally |
| Semaglutide C Dose 5 (50 mg) | DRUG | Tablet given orally |
| Placebo (Semaglutide C) | DRUG | Tablet given orally |
| Placebo ( Semaglutide D) | DRUG | Tablet given orally |
| Semaglutide Dose 4 | DRUG | Tablet given orally |
| Semaglutide Dose 5 | DRUG | Tablet given orally |
| Semaglutide Dose 6 | DRUG | Tablet given orally |
| Semaglutide D | DRUG | Tablet given orally |
| Semaglutide G | DRUG | Tablet given orally |
| Semaglutide H | DRUG | Tablet given orally |
| Semaglutide I | DRUG | Tablet given orally |
| NNC0385-0434 B | DRUG | Tablet given orally |
| NNC0385-0434 C | DRUG | Tablet given orally |
| NNC0385-0434 D | DRUG | Tablet given orally |
| NNC0385-0434 E | DRUG | Tablet given orally |
Inclusion Criteria: * Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent * Body mass index between 30.0 and 45.0 kilogram per meter square (kg/m\^2) (both inclusive) Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant o...
Semaglutide D Dose 1 is an investigational oral formulation of semaglutide being developed by Novo Nordisk A/S. It is a small molecule GLP-1 receptor agonist studied in Phase 1 clinical trials for obesity, type 2 diabetes, and high blood cholesterol levels. It has not been approved by the FDA and remains in clinical development.
Semaglutide D Dose 1 targets GLP1R, the glucagon-like peptide-1 receptor, and acts as a receptor agonist. By activating GLP1R, the drug mimics the action of the endogenous incretin hormone GLP-1, which is involved in regulating appetite, food intake, and glucose-dependent insulin secretion.
Semaglutide D Dose 1 is developed by Novo Nordisk A/S, the Danish pharmaceutical company whose shares trade under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 clinical program evaluating this oral semaglutide formulation.
Semaglutide D Dose 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 1 program has been completed, with no active trials currently listed for this specific formulation.
Semaglutide D Dose 1 has been evaluated in Phase 1 trials including NCT05236517, which studied 50 mg semaglutide daily and its effects on food intake and stomach emptying in people with obesity, and NCT05227196, which compared two oral semaglutide forms in healthy participants and those with type 2 diabetes.